{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T10:03:35Z","timestamp":1789639415440,"version":"4.0.0"},"reference-count":20,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2016,6,15]],"date-time":"2016-06-15T00:00:00Z","timestamp":1465948800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vet Pharm &amp; Therapeutics"],"published-print":{"date-parts":[[2017,4]]},"abstract":"<jats:p>The objective of this study was to gain an understanding of the pharmacokinetic and pharmacodynamic properties of pergolide in horses with <jats:styled-content style=\"fixed-case\">PPID<\/jats:styled-content> after of long\u2010term oral administration. Six horses with confirmed <jats:styled-content style=\"fixed-case\">PPID<\/jats:styled-content> were treated with pergolide (Prascend<jats:sup>\u00ae<\/jats:sup>) at 1\u00a0mg\/horse po q24\u00a0h for 2\u00a0months, followed by 2\u00a0mg\/horse po q24\u00a0h for 4\u00a0months. Following the last dose, plasma samples were collected for measurement of pergolide using an <jats:styled-content style=\"fixed-case\">LC<\/jats:styled-content>\/<jats:styled-content style=\"fixed-case\">MS<\/jats:styled-content>\/<jats:styled-content style=\"fixed-case\">MS<\/jats:styled-content> method and <jats:styled-content style=\"fixed-case\">ACTH<\/jats:styled-content> measurement using a chemiluminescent immunoassay. Noncompartmental and compartmental pharmacokinetic analyses were performed, as well as pharmacodynamic assessment of the effect of plasma pergolide concentrations on plasma <jats:styled-content style=\"fixed-case\">ACTH<\/jats:styled-content> concentrations. Pergolide effectively decreased plasma <jats:styled-content style=\"fixed-case\">ACTH<\/jats:styled-content> concentration in aged horses with <jats:styled-content style=\"fixed-case\">PPID<\/jats:styled-content>, with similar pharmacokinetic properties as reported in young horses, including an approximate terminal half\u2010life of 24\u00a0h. Plasma <jats:styled-content style=\"fixed-case\">ACTH<\/jats:styled-content> concentration increased by 50% in 3\/6 horses at 2\u00a0days and 6\/6 horses 10\u00a0days after discontinuing drug administration. Pergolide was quantified in all horses at 2\u00a0days and in none at 10\u00a0days after last dose. In summary, after discontinuing pergolide treatment, plasma <jats:styled-content style=\"fixed-case\">ACTH<\/jats:styled-content> concentration increased while pergolide was still quantifiable in some horses. Once\u2010daily dosing of pergolide is likely appropriate in most horses with <jats:styled-content style=\"fixed-case\">PPID<\/jats:styled-content> for regulating the plasma <jats:styled-content style=\"fixed-case\">ACTH<\/jats:styled-content> concentration.<\/jats:p>","DOI":"10.1111\/jvp.12339","type":"journal-article","created":{"date-parts":[[2016,6,15]],"date-time":"2016-06-15T14:06:31Z","timestamp":1465999591000},"page":"158-164","source":"Crossref","is-referenced-by-count":24,"title":["Pharmacokinetic and pharmacodynamic properties of pergolide mesylate following long\u2010term administration to horses with pituitary pars intermedia dysfunction"],"prefix":"10.1111","volume":"40","author":[{"given":"D.","family":"McFarlane","sequence":"first","affiliation":[{"name":"Center for Veterinary Health Sciences Physiological Sciences Oklahoma State University Stillwater OK USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Banse","sequence":"additional","affiliation":[{"name":"Center for Veterinary Health Sciences Physiological Sciences Oklahoma State University Stillwater OK USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. K.","family":"Knych","sequence":"additional","affiliation":[{"name":"K.L. Maddy Equine Analytical Chemistry Laboratory School of Veterinary Medicine University of California Davis CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L. K.","family":"Maxwell","sequence":"additional","affiliation":[{"name":"Center for Veterinary Health Sciences Physiological Sciences Oklahoma State University Stillwater OK USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2016,6,15]]},"reference":[{"key":"e_1_2_5_2_1","doi-asserted-by":"publisher","DOI":"10.2460\/javma.231.3.417"},{"key":"e_1_2_5_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1939-1676.2002.tb02418.x"},{"key":"e_1_2_5_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1939-1676.2005.tb02685.x"},{"key":"e_1_2_5_5_1","unstructured":"FDA FOIADrugSummaries\/UCM280354. Available at:http:\/\/www.fda.gov\/downloads\/AnimalVeterinary\/Products\/ApprovedAnimalDrugProducts\/FOIADrugSummaries\/UCM280354.pdf."},{"key":"e_1_2_5_6_1","unstructured":"Frank N. Andrews F. Durham A Kritchevsky J. McFarlane D.&Schott H. (2015)Recommendations for the diagnosis and treatment of pituitary pars intermedia dysfunction (PPID). Available at:https:\/\/sites.tufts.edu\/equineendogroup\/files\/2015\/12\/2015-10-16_EEG-2015-recommendations.pdf"},{"key":"e_1_2_5_7_1","first-page":"E1","article-title":"Single\u2010dose oral pharmacokinetics of pergolide mesylate in healthy adult mares","volume":"11","author":"Gehring R.","year":"2010","journal-title":"Veterinary Therapeutics: Research in Applied Veterinary Medicine"},{"key":"e_1_2_5_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.2042-3306.2010.00361.x"},{"key":"e_1_2_5_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2014.01.016"},{"key":"e_1_2_5_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cveq.2010.12.007"},{"key":"e_1_2_5_11_1","doi-asserted-by":"publisher","DOI":"10.2460\/ajvr.2004.65.1463"},{"key":"e_1_2_5_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2826.2005.01277.x"},{"key":"e_1_2_5_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1939-1676.2011.0745.x"},{"key":"e_1_2_5_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.2042-3306.2012.00578.x"},{"key":"e_1_2_5_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/0016-6480(92)90014-B"},{"key":"e_1_2_5_16_1","doi-asserted-by":"publisher","DOI":"10.1210\/endo-110-4-1430"},{"key":"e_1_2_5_17_1","doi-asserted-by":"publisher","DOI":"10.2746\/042516402776250333"},{"key":"e_1_2_5_18_1","doi-asserted-by":"publisher","DOI":"10.2460\/ajvr.76.2.155"},{"key":"e_1_2_5_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0749-0739(02)00018-4"},{"key":"e_1_2_5_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-3164.2004.00410_2-7.x"},{"key":"e_1_2_5_21_1","doi-asserted-by":"publisher","DOI":"10.2460\/javma.241.2.241"}],"container-title":["Journal of Veterinary Pharmacology and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjvp.12339","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjvp.12339","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jvp.12339","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T18:44:04Z","timestamp":1696185844000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jvp.12339"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6,15]]},"references-count":20,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,4]]}},"alternative-id":["10.1111\/jvp.12339"],"URL":"https:\/\/doi.org\/10.1111\/jvp.12339","archive":["Portico"],"relation":{},"ISSN":["0140-7783","1365-2885"],"issn-type":[{"value":"0140-7783","type":"print"},{"value":"1365-2885","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,6,15]]}}}